In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Ionis Pharmaceuticals Inc’s stock clocked out at $69.96, up 1.48% from its previous closing price of $68.94. In other words, the price has increased by $1.48 from its previous closing price. On the day, 3.1 million shares were traded. IONS stock price reached its highest trading level at $71.87 during the session, while it also had its lowest trading level at $69.6.
Ratios:
To gain a deeper understanding of IONS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 06 ’25 when Swayze Eric sold 6,849 shares for $69.02 per share. The transaction valued at 472,718 led to the insider holds 30,453 shares of the business.
O’NEIL PATRICK R. sold 13,441 shares of IONS for $937,338 on Oct 06 ’25. The EVP CLO & General Counsel now owns 53,889 shares after completing the transaction at $69.74 per share. On Oct 06 ’25, another insider, Monia Brett P, who serves as the Chief Executive Officer of the company, sold 437 shares for $69.26 each. As a result, the insider received 30,268 and left with 179,572 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 11151010816 and an Enterprise Value of 10842043392. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.81 while its Price-to-Book (P/B) ratio in mrq is 17.63. Its current Enterprise Value per Revenue stands at 11.485 whereas that against EBITDA is -42.489.
Stock Price History:
The Beta on a monthly basis for IONS is 0.32, which has changed by 0.8434782 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $70.14, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 29.79%, while the 200-Day Moving Average is calculated to be 79.02%.
Shares Statistics:
It appears that IONS traded 2.41M shares on average per day over the past three months and 2206300 shares per day over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 158.18M. Insiders hold about 0.77% of the company’s shares, while institutions hold 106.86% stake in the company. Shares short for IONS as of 1757894400 were 11972594 with a Short Ratio of 4.96, compared to 1755216000 on 10785168. Therefore, it implies a Short% of Shares Outstanding of 11972594 and a Short% of Float of 9.9700004.
Earnings Estimates
The company has 8.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.95 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$1.63 and -$2.49 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.96, with 11.0 analysts recommending between -$0.46 and -$3.17.
Revenue Estimates
In. The current quarter, 18 analysts expect revenue to total $132.18M. It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 18 analysts are estimating revenue of $145.16M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.
A total of 24 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $832.78M, resulting in an average revenue estimate of $865.86M. In the same quarter a year ago, actual revenue was $705MBased on 23 analysts’ estimates, the company’s revenue will be $898.97M in the next fiscal year. The high estimate is $1.15B and the low estimate is $681.53M.
